Decision Support in New Jersey

Talshir Medical Technologies Ltd., operating as RevitalVision, develops FDA-cleared perceptual learning and vision training software designed to improve the brain's visual processing. RevitalVision is indicated for amblyopia (lazy eye) in patients aged 9 and older, making it the only FDA-cleared product with efficacy claims for adult amblyopia as a standalone therapy without upper age limits. The platform uses proprietary perceptual learning technology supported by randomized controlled, double-blind clinical studies published in peer-reviewed journals. Beyond amblyopia treatment, RevitalVision addresses post-cataract surgery vision recovery, low myopia, presbyopia (read without glasses), sports vision enhancement, post-LASIK vision improvement, and low vision from eye diseases. Clinical evidence demonstrates an average 2.5-line improvement on ETDRS visual acuity charts, 100% improvement in contrast sensitivity (FACT sine wave), and enhanced stereo and binocular functions. The company operates a B2B2C model where ophthalmologists, optometrists, orthoptists, and optometry doctors subscribe to monthly or annual plans, then offer therapy programs to patients. Training sessions are administered at-home (3–4 per week) with periodic in-clinic assessments. The American Medical Association has assigned two unique CPT codes (0687T and 0688T) for RevitalVision amblyopia therapy, effective January 2022, supporting insurance coverage pathways. More than 30 clinical studies across the USA, Europe, and Asia support efficacy, with 12 published in peer-reviewed journals. The company operates globally with approximately 400 clinics and 15,000 treated patients reported.

Curio Digital Therapeutics develops AI-driven digital-first behavioral health solutions specifically for women's mental health across fertility, pregnancy, postpartum, and menopause life stages. The company offers Prescription Digital Therapeutic (PDT) products FDA-authorized for postpartum depression treatment, complemented by coaching and therapist-supported programs. Core offerings include MamaLift and MamaLift Plus, on-demand digital therapy platforms featuring evidence-based cognitive behavioral therapy (CBT) lessons, health trackers, and live health coach support. Curio-I is an AI-powered predictive platform for early identification and risk stratification of mental health disorders affecting women. All products are validated through clinical trials, with seven published studies demonstrating clinical efficacy. The platform operates on cloud-first, mobile-first architecture enabling anytime, anywhere access. Early adopters and partners include Mount Sinai Health System, Columbia University, and various health plans. The company has received recognition from Business Insider, BioNJ, and innovation awards including Point32 and MassChallenge. Product outcomes show 2 of 3 women achieving symptom improvement below depression thresholds, 70% user referral rates, and 5:1 return on investment metrics.

Clario (formerly Bioclinica) is a global clinical trial endpoint technology platform and services provider with 50+ years of expertise supporting drug development. The company delivers comprehensive solutions for efficacy, safety, and patient quality-of-life assessments across decentralized, hybrid, and site-based clinical trials in over 100 countries. Clario's integrated platform combines clinical trial management software, connected medical devices, and AI-powered solutions spanning cardiac safety monitoring, electronic clinical outcomes assessment (eCOA), medical imaging with imaging core lab services, precision motion analysis, and respiratory endpoints. With experience managing 30,000+ trials contributing to 700+ FDA/EMA new drug approvals, Clario employs 3,900+ professionals including 200+ therapeutic area specialists. The platform emphasizes regulatory compliance, patient-centric design, global multilingual deployment, and 24/7 operational support to simplify trial processes for sponsors, contract research organizations (CROs), and research sites.

HealthArc is a comprehensive digital health platform specializing in remote patient monitoring (RPM), chronic care management (CCM), and care coordination software for healthcare providers. The platform integrates with over 40 compatible medical devices (blood pressure monitors, glucometers, pulse oximeters, weight scales, spirometers, continuous glucose monitors, thermometers, and medication adherence trackers) to enable real-time vital sign monitoring and patient data collection. HealthArc's unified care platform features AI-driven clinical pathways, automated workflow management, and intelligent patient communication via SMS and phone escalation. The software supports multiple CMS-compliant care programs including Remote Patient Monitoring, Chronic Care Management, Principal Care Management, Remote Therapeutic Monitoring, Transitional Care Management, Medication Therapy Management, Behavioral Health Integration, and Advanced Primary Care Management. The platform automates billing documentation and claims submission across these programs, integrates with existing EHR systems, and includes specialized clinical support services with enrollment specialists, RNs, LPNs, and medical assistants. HealthArc serves hospitals, primary care practices, virtual care delivery companies, and managed healthcare organizations, with current deployment across 40+ states serving 750+ providers and 65,000+ patients. The company prioritizes HIPAA compliance, SOC2 certification, and FDA-approved device integration.

Scopio Labs Ltd. develops Full-Field digital imaging and analysis platforms for clinical hematopathology, specifically targeting peripheral blood smear and bone marrow aspirate morphology assessment. The company manufactures high-resolution digital scanning devices and proprietary software that replaces traditional light microscopy with 100x dynamic full-field imaging, enabling remote viewing, collaboration, and standardized cell morphology analysis across laboratory networks. The platform includes AI-assisted decision support for autonomous cell differential counting and morphologic classification, addressing critical labor shortages and standardization challenges in hematology laboratories. Products include Peripheral Blood Smear Application (CE-marked, FDA-cleared for commercial use in US, UK, Europe, and other territories), Full-Field Bone Marrow Aspirate Application (CE-marked, cleared in select regions outside the US), and the upcoming Complete Blood Morphology (CBM) autonomous analysis system. The company partners with major hematology and pathology networks including Synnovis, Mount Sinai, PathGroup, Synlab, and others. Scopio's technology addresses rising testing volumes, critical staffing shortages, operator variability reduction, and enables 24/7 remote expert consultation without microscope dependency or on-site presence requirements.